GlassScriptPhysician profile
Matthew D Larson
NPI 1346703634
$1,164.95
in general payments reported to CMS, 2019-2025
14 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2023: $225 · 2024: $391 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $715.79 | 2021-2025 | Ams 700, Advance Xp, Lithovue Elite |
| Janssen Biotech, INC. | $127.36 | 2025 | Rybrevant, Carvykti, Erleada |
| Histosonics, INC. | $51.96 | 2025 | |
| Antares Pharma, INC. | $34.94 | 2025 | Xyosted |
| Intuitive Surgical, INC. | $33.38 | 2021 | |
| Organogenesis INC. | $30.11 | 2025 | Puraply Wound Matrix |
| Procept Biorobotics Corporation | $24.93 | 2025 | |
| Allergan, INC. | $24.40 | 2021 | |
| Teleflex LLC | $22.94 | 2025 | Urolift |
| Immunitybio, INC. | $20.97 | 2025 | |
| Urogen Pharma, INC. | $20.85 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $20.38 | 2025 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire |
| Sumitomo Pharma America, INC. | $18.60 | 2024 | Orgovyx |
| Astrazeneca Pharmaceuticals LP | $18.34 | 2025 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.